References
- ST Lim, Siew WH, Quek R, LC Lim, SP Yap, Loong EL, . Comparative analysis of extranodal NK/T cell lymphoma and peripheral T cell lymphoma: Significant differences in clinical characteristics and prognosis. Eur J Haematol 2008;80:55–60.
- Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally natural killer cells and inhibition of P-glycoprotein function by cyclosporine A and its analogue, PSC833. Blood 1999;93: 599–606.
- Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, . Phase I study of dexamethasone, methotrexate, ifosfamide, L-Asparaginase and etoposide (SMILE) chemotherapy for advanced stage, relapsed or refractory extranodal natural killer (NK)/T cell lymphoma and leukemia. Cancer Sci 2008;99:1016–20.
- Loong SL, Hwang JS, Lim ST, Yap SP, Tao M, Chong TW, . An Epstein Barr Virus positive natural killer lymphoma xenograft derived for drug testing. Leuk Lymphoma 2008; 49:1161–7.
- GC Koo, W Esa, ST Lim, SY Tan, S Loong. Evaluation of the efficacy of selected chemotherapeutic and immunotherapeutic drugs in NK/T non-Hodgkin's lymphoma xenograft model. Poster 023. BIT Life Sciences’ 2nd Annual World Cancer Congress 2009, Beijing, China.
- Fosså A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, . Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3786–92.
- Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, . Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000;11:595–7.
- Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic and phase I studies of Gemcitabine. Semin Oncol 1997;24(2 Suppl 7):S7-2–S7-7.
- Hagemeister FB, Diehl V. The role of ifosfamide in cytoreduction, stem cell mobilization and high dose therapy in relapsed/refractory malignant lymphomas. Eur J Haematol Suppl 2001;64:1–2.
- Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, . Phase II study of oxaliplatin in patients with recurrent or refractory non Hodgkin's lymphoma. Cancer 2005;104:781–7.
- Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117–23.